Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030949062> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W3030949062 abstract "3575 Background: Patients (pts) treated with checkpoint inhibitors (CPI) may uncommonly experience accelerated progression in their tumor burden when compared to their rate of progression prior to receiving CPI. This hyperprogression has been varyingly defined and no biomarker has yet been identified. Methods: We reviewed the database from the Tumor Response Assessment Core (TRAC) at University of Michigan to identify these patients. Hyperprogression was defined as increase in tumor burden per specific immune RECIST criteria by at least 40% from baseline on the first follow-up scan with a minimum increase of 10 mm, and at least 2 times rate of growth than observed prior to start of CPI therapy. Results: Out of 741 pts who underwent baseline and 1st follow-up assessment enrolled on 118 trials, 302 (34.4%) pts received immunotherapy alone or in combination with chemotherapy/targeted agents across 49 trials. Of them, 15 pts (5%) with 5 females (33%) and median age of 63 years (range, 44 -72) met criteria for hyperprogression. The primary cancers included lung (5), colorectal (2), renal (2), biliary (1), pancreatic (1), esophageal (1), bladder (1), small bowel (1), and melanoma (1). The median time to hyperprogression was 67 (range 42-110) days, and the mean survival was 7.9 months from trial enrollment. We did not identify any clinical factor or specific CPI therapy that associated with hyperprogression. Exploratory biomarker analysis of genomic (gene panel assay) and immune subsets of tissue microenvironment (multiplex staining) is underway. Conclusions: This is the largest cohort investigated for hyperprogression across multiple cancers in literature. The rate of hyperprogression observed is less than previously reported in literature, and physicians need to be aware of this possibility while administering CPI to their patients." @default.
- W3030949062 created "2020-06-05" @default.
- W3030949062 creator A5024995156 @default.
- W3030949062 creator A5068806294 @default.
- W3030949062 creator A5071834540 @default.
- W3030949062 creator A5076767039 @default.
- W3030949062 creator A5082008260 @default.
- W3030949062 date "2020-05-20" @default.
- W3030949062 modified "2023-10-17" @default.
- W3030949062 title "Hyperprogression in cancer patients on immunotherapeutic agents." @default.
- W3030949062 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.3575" @default.
- W3030949062 hasPublicationYear "2020" @default.
- W3030949062 type Work @default.
- W3030949062 sameAs 3030949062 @default.
- W3030949062 citedByCount "0" @default.
- W3030949062 crossrefType "journal-article" @default.
- W3030949062 hasAuthorship W3030949062A5024995156 @default.
- W3030949062 hasAuthorship W3030949062A5068806294 @default.
- W3030949062 hasAuthorship W3030949062A5071834540 @default.
- W3030949062 hasAuthorship W3030949062A5076767039 @default.
- W3030949062 hasAuthorship W3030949062A5082008260 @default.
- W3030949062 hasConcept C121608353 @default.
- W3030949062 hasConcept C126322002 @default.
- W3030949062 hasConcept C143998085 @default.
- W3030949062 hasConcept C185592680 @default.
- W3030949062 hasConcept C2777701055 @default.
- W3030949062 hasConcept C2780030458 @default.
- W3030949062 hasConcept C2780057760 @default.
- W3030949062 hasConcept C2780210213 @default.
- W3030949062 hasConcept C2781197716 @default.
- W3030949062 hasConcept C526805850 @default.
- W3030949062 hasConcept C535046627 @default.
- W3030949062 hasConcept C55493867 @default.
- W3030949062 hasConcept C71924100 @default.
- W3030949062 hasConcept C72563966 @default.
- W3030949062 hasConceptScore W3030949062C121608353 @default.
- W3030949062 hasConceptScore W3030949062C126322002 @default.
- W3030949062 hasConceptScore W3030949062C143998085 @default.
- W3030949062 hasConceptScore W3030949062C185592680 @default.
- W3030949062 hasConceptScore W3030949062C2777701055 @default.
- W3030949062 hasConceptScore W3030949062C2780030458 @default.
- W3030949062 hasConceptScore W3030949062C2780057760 @default.
- W3030949062 hasConceptScore W3030949062C2780210213 @default.
- W3030949062 hasConceptScore W3030949062C2781197716 @default.
- W3030949062 hasConceptScore W3030949062C526805850 @default.
- W3030949062 hasConceptScore W3030949062C535046627 @default.
- W3030949062 hasConceptScore W3030949062C55493867 @default.
- W3030949062 hasConceptScore W3030949062C71924100 @default.
- W3030949062 hasConceptScore W3030949062C72563966 @default.
- W3030949062 hasLocation W30309490621 @default.
- W3030949062 hasOpenAccess W3030949062 @default.
- W3030949062 hasPrimaryLocation W30309490621 @default.
- W3030949062 hasRelatedWork W15827158 @default.
- W3030949062 hasRelatedWork W2151330 @default.
- W3030949062 hasRelatedWork W3521414 @default.
- W3030949062 hasRelatedWork W6189649 @default.
- W3030949062 hasRelatedWork W6663085 @default.
- W3030949062 hasRelatedWork W7677563 @default.
- W3030949062 hasRelatedWork W7733468 @default.
- W3030949062 hasRelatedWork W9153885 @default.
- W3030949062 hasRelatedWork W9749177 @default.
- W3030949062 hasRelatedWork W9981307 @default.
- W3030949062 isParatext "false" @default.
- W3030949062 isRetracted "false" @default.
- W3030949062 magId "3030949062" @default.
- W3030949062 workType "article" @default.